BSD Medical submissions update
This article was originally published in The Gray Sheet
Executive Summary
BSD Medical will submit data on about 400 additional patients treated with its BSD-2000 hyperthermia system for cancer treatment as part of a formal response to FDA's request for more information on a PMA application submitted in May 2006, the firm says June 30. Most of the data supporting the original PMA submission came from European clinical studies (1"The Gray Sheet" Jan. 9, 2006, p. 15)
You may also be interested in...
BSD Medical Plans To File PMA For Cancer Therapy, Prepares Japanese Strategy
BSD Medical plans to submit a PMA application by the end of the quarter for its non-invasive BSD-2000 tumor hyperthermia therapy system to treat cancer
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.